; and (ii) requesting that the hospital or other clinical setting provide to the com­pound­ing pharmacist or physician the records that identify the patient or patients to whom the drug products were administered within— (I) 7 days of each such patient receiving such medication; or (II) 7 days of each such patient being discharged. (D) Upon receipt of records requested pursuant to subparagraph (C)(ii), the licensed pharmacist or licensed physician ensures that the patient information in such records is linked with the respective order. (E) The licensed pharmacist or licensed physician reports adverse events associated with the compounded drug product as soon as possible but no later than 15 days after becoming aware of such events to the MedWatch Adverse Event Reporting program of the Food and Drug Administration (or any successor program). . 3. Compounding for shortages for administration in hospitals or other clinical settings Paragraph (2) of section 503A(b) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 353a(b)(2) ) is amended to read as follows: (2) Definition For purposes of paragraph (1)(D), the term essentially a copy of a commercially available drug product does not include— (A) a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product; or (B) a drug product that meets each of the following conditions: (i) At the time of compounding, distribution, or dispensing, the drug product appears on— (I) the drug shortage list in effect under section 506E